MorphoSys AG — Regulatory Filings 2002

Aug 7, 2002

News Details

Corporate | 7 August 2002 08:00

MorphoSys AG english

MorphoSys Celebrates 10 Year Anniversary Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– The Munich-based biotechnology company, MorphoSys AG (Neuer Markt: MOR) yesterday celebrated the Company’s 10th anniversary since its founding in 1992. The festivities took place with several national and international guests in attendance at MorphoSys’ premises in Martinsried near Munich. Among the guest speakers was Bavarian Minister for Economic Affairs, Transport and Technology, Dr. Otto Wiesheu, who underscored the pioneering role of MorphoSys in the German biotechnology sector. In a very visible initial public offering in March 1999, MorphoSys was the first German biopharmaceutical company to go public, thereby helping to establish the biotechnology sector in Germany. With partnerships including several renowned pharma- and biotechnology companies such as Bayer, Schering, Centocor and Roche, MorphoSys has established itself as a globally recognized leader in the field of human antibodies. More recently, the Company expanded its business model to include the development of own therapeutic antibodies. Presently the MorphoSys Group employs 130 persons and generated revenues of EUR 16.1 million in 2001. “We are very proud about the success we have achieved so far,” said Dr. Simon Moroney, co-founder and CEO of MorphoSys AG, during the ceremony. “With an excellent team and a powerful technology, we are well prepared for the future.” end of message, (c)DGAP 07.08.2002 ——————————————————————————– WKN: 663200; ISIN: DE0006632003; Index: Nemax 50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 070800 Aug 02